Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Integrase (IN) strand transfer inhibitors (INSTIs) have been developed to inhibit the ability of HIV-1 integrase to irreversibly link the reverse-transcribed viral DNA to the host genome. INSTIs have proven their high efficiency in inhibiting viral replication in vitro and in patients. However, first-generation INSTIs have only a modest genetic barrier to resistance, allowing the virus to escape these powerful drugs through several resistance pathways. Second-generation INSTIs, such as dolutegravir (DTG, S/GSK1349572), have been reported to have a higher resistance barrier, and no novel drug resistance mutation has yet been described for this drug. Therefore, we performed in vitro selection experiments with DTG using viruses of subtypes B, C, and A/G and showed that the most common mutation to emerge was R263K. Further analysis by site-directed mutagenesis showed that R263K does confer low-level resistance to DTG and decreased integration in cell culture without altering reverse transcription. Biochemical cell-free assays performed with purified IN enzyme containing R263K confirmed the absence of major resistance against DTG and showed a slight decrease in 3′ processing and strand transfer activities compared to the wild type. Structural modeling suggested and in vitro IN-DNA binding assays show that the R263K mutation affects IN-DNA interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569 · cited 1×
“(13, 53, 54, 65, 73), PM1 from Marvin Reitz (37), pNL4-3 from Malcolm Martin (1), and HIV-1 HXB2 integrase antiserum (no.”
MethodRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678 · cited 5×
“Accordingly, we used Protein Data Bank (PDB) identification numbers 3L2R (26), 3S3M (27), and 3OS0 (39) as starting points for structural refinement of wild-type and R263K intasomes, drug-bound intasome, and STC, respectively.”
BackgroundMethodInfluentialBukrinsky, M. I., Sharova, N., McDonald, T. L., Pushkarskaya, T., Tarpley, W. G., & Stevenson, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6125 · Cited by 451
Chen, J. C.-H., Krucinski, J., Miercke, L. J. W., Finer-Moore, J. S., Tang, A. H., Leavitt, A. D., & Stroud, R. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150220297 · Cited by 404 · cited 1×
“available partial crystal structures of HIV-1 integrase (8, 25, 40, 72) and”
BackgroundGrobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092056199 · Cited by 399 · cited 1×
“Even though 3= processing may be a suitable therapeutic target, the integrase inhibitors developed so far are integrase strand transfer inhibitors (INSTIs) that preferentially inhibit strand transfer while only modestly affecting 3= processing (18, 24, 26).”
BackgroundEspeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317 · cited 2×
“Even though 3= processing may be a suitable therapeutic target, the integrase inhibitors developed so far are integrase strand transfer inhibitors (INSTIs) that preferentially inhibit strand transfer while only modestly affecting 3= processing (18, 24, 26).”
BackgroundThe mechanism of retroviral integration from X-ray structures of its key intermediates
Maertens, G. N., Hare, S., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature09517 · Cited by 296 · cited 4×
“Homology models of full-length HIV-1 IN intasome and strand transfer complex (STC) were created based on the available partial crystal structures of HIV-1 integrase (8, 25, 40, 72) and the published intasome (26) and STC (39) of the prototype foamy virus (PFV) using the I-TASSER three-dimensional (3D) protein predicti…”
BackgroundMethodInfluentialDeJesus, E., Berger, D., Markowitz, M., Cohen, C., Hawkins, T., Ruane, P., Elion, R., Farthing, C., Zhong, L., Cheng, A. K., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000233308.82860.2f · Cited by 270 · cited 1×
“Elvitegravir (EVG) is another INSTI currently in advanced clinical trials (10, 12, 77).”
BackgroundHare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073189 · Cited by 264
Structural Basis for Functional Tetramerization of Lentiviral Integrase
Hare, S., Di Nunzio, F., Labeja, A., Wang, J., Engelman, A., & Cherepanov, P. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000515 · Cited by 122
Cited by
Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01474-16 · Cited by 290
Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome
Passos, D. O., Li, M., Yang, R., Rebensburg, S. V., Ghirlando, R., Jeon, Y., Shkriabai, N., Kvaratskhelia, M., Craigie, R., & Lyumkis, D. (2017) · Science · doi:10.1126/science.aah5163 · Cited by 202
“R263K mutants decreased integration in cell culture, but also conferred low-level resistance to an INSTI (52); the compromised catalytic activity of the R263K virus is likely due to the multiple relevant”
BackgroundInfluentialEfficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018) · Retrovirology · doi:10.1186/s12977-018-0420-7 · Cited by 114
Crystal structure of the Rous sarcoma virus intasome
Yin, Z., Shi, K., Banerjee, S., Pandey, K. K., Bera, S., Grandgenett, D. P., & Aihara, H. (2016) · Nature · doi:10.1038/nature16950 · Cited by 95
“2b), which could be relevant to the effect of mutation of the corresponding HIV-1 residue Arg263 on catalysis and drug resistance 19 .”
Hassounah, S. A., Alikhani, A., Oliveira, M., Bharaj, S., Ibanescu, R.-I., Osman, N., Xu, H.-T., Brenner, B. G., Mesplède, T., & Wainberg, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01695-17 · Cited by 40
Self-citation
Metadata
- Authors
- Quashie, P. K., Mesplède, T., Han, Y.-S., Oliveira, M., Singhroy, D. N., Fujiwara, T., Underwood, M. R., & Wainberg, M. A.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2012-03
- Volume
- 86
- Issue
- 5
- Pages
- 2696-2705
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2057925552
- Cited by
- 237
- References
- 11
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir. https://app.cochat.ai/papers/10.1128/jvi.06591-11
- The paper
- Quashie, P. K., Mesplède, T., Han, Y.-S., Oliveira, M., Singhroy, D. N., Fujiwara, T., Underwood, M. R., & Wainberg, M. A. (2012). Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir. Journal of Virology. https://doi.org/10.1128/jvi.06591-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.